Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Universiti Sains Malaysia

Status and phase: Completed; Phase 3; Phase 2

Conditions: Pterygium

Treatments: Drug: ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT02342392

1

Details and patient eligibility

About

The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

Full description

The purpose of this study is to:

1. Compare the vascularity of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 mL) injection.
2. Compare the size of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 mL) injection.
3. Compare the recurrence rate at 1 year after pterygium excision surgery between the group with and without intralesional ranibizumab injection.

Enrollment: 36 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients with primary pterygium.
• Grade T3 (fleshy) pterygium.

Exclusion criteria

• Patients with other ocular surface disorders.
• Previous ocular surgery or trauma.
• History of systemic thromboembolic event.
• Pregnant women and lactating mother.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

36 participants in 2 patient groups

treatment group

Active Comparator group

Description:

intralesional ranibizumab injected

Treatment:

Drug: ranibizumab

control group

No Intervention group

Description:

no intralesional ranibizumab injected.